Sales 2024 * | 35M 25.58M | Sales 2025 * | 38.7M 28.28M | Capitalization | 116M 84.71M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 3.31 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3 x |
P/E ratio 2024 * |
18.2
x | P/E ratio 2025 * |
15.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.64% |
Latest transcript on Biosyent Inc.
Managers | Title | Age | Since |
---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 64 | 95-12-31 |
Robert March
DFI | Director of Finance/CFO | - | 18-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 14-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sara Elford
BRD | Director/Board Member | 53 | 18-01-07 |
René Goehrum
CEO | Chief Executive Officer | 64 | 95-12-31 |
Peter Lockhard
BRD | Director/Board Member | 60 | 02-05-31 |
1st Jan change | Capi. | |
---|---|---|
+55.35% | 815B | |
+32.62% | 597B | |
-0.10% | 377B | |
+15.47% | 319B | |
+13.10% | 310B | |
+16.36% | 247B | |
+14.80% | 228B | |
+16.54% | 180B | |
+4.31% | 170B |